Harnessing exosomes as cancer biomarkers in clinical oncology.

Exosomes are extracellular vesicles well known for facilitating cell-to-cell communication by distributing essential macromolecules like proteins, DNA, mRNA, lipids, and miRNA. These vesicles are abundant in fluids distributed throughout the body, including urine, blood, saliva, and even bile. They are important diagnostic tools for breast, lung, gastrointestinal cancers, etc. However, their application as cancer biomarkers has not yet been implemented in most parts of the world. In this review, we discuss how OMICs profiling of exosomes can be practiced by substituting traditional imaging or biopsy methods for cancer detection. Previous methods like extensive imaging and biopsy used for screening were expensive, mostly invasive, and could not easily provide early detection for various types of cancer. Exosomal biomarkers can be utilized for routine screening by simply collecting body fluids from the individual. We anticipate that the use of exosomes will be brought to light by the success of clinical trials investigating their potential to enhance cancer detection and treatment in the upcoming years.

A novel clinical signature predicts the survival of elderly patients with oral squamous cell carcinoma.

BACKGROUND: The risk factors for the survival of elderly patients with oral squamous cell carcinoma (OSCC) are multifarious. Here, we developed a novel clinical signature to serve as an indicator of prognosis in these patients. MATERIALS AND METHODS: Clinicopathological data were collected for 554 patients aged ≥ 60 years who were treated for primary OSCC. Overall survival (OS), disease-specific survival, and disease-free survival were the primary outcomes. RESULTS: Multivariate cox regression analysis showed that high N stage, low hemoglobin level, low body mass index (BMI), and high neutrophil-to-lymphocyte ratio (NLR) showed a poor survival (P < 0.05). A nomogram was constructed with a c-index of 0.702. CONCLUSION: A novel clinical signature including hemoglobin level, BMI, and NLR, which are obtained through noninvasive examinations can be used as prognostic indicators in clinical practice for elderly patients with OSCC.

Tinnitus: A Dimensionally Segregated, yet Perceptually Integrated Heterogeneous Disorder.

OBJECTIVES: Tinnitus subtypes are proposed to lie on a continuum of different symptom dimensions rather than be categorical. However, there is no comprehensive empirical data showing this complex relationship between different tinnitus symptoms. The objective of this study is to provide empirical evidence for the dimensional nature of tinnitus and how different auditory and non-auditory symptoms interact with each other through complex interactions. We do this using graph theory, a mathematical tool that empirically maps this complex interaction. This way, graph theory can be utilised to highlight a new and possibly important outlook on how we can understand the heterogeneous nature of tinnitus. DESIGN: In the current study, we use the screening databases of the Treatment Evaluation of Neuromodulation for Tinnitus-Stage A1 (TENT-A1) and A2 (TENT-A2) randomised trials to delineate the dimensional relationship between different clinical measures of tinnitus as a secondary data analysis. We first calculate the empirical relationship by computing the partial correlation. Following this, we use different measures of centrality to describe the contribution of different clinical measures to the overall network. We also calculate the stability of the network and compare the similarity and differences between TENT-A1 and TENT-A2. RESULTS: Components of the auditory subnetwork (loudness discomfort level, sound sensitivity, average hearing loss and high frequency hearing loss) are highly inter-connected in both networks with sound sensitivity and loudness discomfort level being highly influential with high measures of centrality. Furthermore, the relationship between the densely connected auditory subnetwork with tinnitus-related distress seems to vary at different levels of distress, hearing loss, duration and age of the participants. CONCLUSION: Our findings provide first-time evidence for tinnitus varying in a dimensional fashion illustrating the heterogeneity of this phantom percept and its ability to be perceptually integrated, yet behaviourally segregated on different symptomatic dimensions.

Brain-clinical signatures for vagus nerve stimulation response.

AIM: Vagus nerve stimulation (VNS) is a valuable treatment for drug-resistant epilepsy (DRE) without the indication of surgical resection. The clinical heterogeneity of DRE has limited the optimal indication of choice and diagnosis prediction. The study aimed to explore the correlations of brain-clinical signatures with the clinical phenotype and VNS responsiveness. METHODS: A total of 89 DRE patients, including VNS- (n = 44) and drug-treated (n = 45) patients, were retrospectively recruited. The brain-clinical signature consisted of demographic information and brain structural deformations, which were measured using deformation-based morphometry and presented as Jacobian determinant maps. The efficacy and presurgical differences between these two cohorts were compared. Then, the potential of predicting VNS response using brain-clinical signature was investigated according to the different prognosis evaluation approaches. RESULTS: The seizure reduction was higher in the VNS-treated group (42.50%) as compared to the drug-treated group (12.09%) (p = 0.11). Abnormal imaging representation, showing encephalomalacia (pcorrected  = 0.03), was commonly observed in the VNS-treated group (p = 0.04). In the patients treated with VNS, the mild/subtle brain abnormalities indicated higher seizure frequency (p = 0.03) and worse VNS response (p = 0.04). The partial least square regression analysis showed a moderate prediction potential of brain-clinical signature for VNS response (p < 0.01). The increase in the pre-VNS seizure frequency and structural etiology could indicate a worse prognosis (higher McHugh classification). CONCLUSION: The brain-clinical signature illustrated its clinical potential in predicting the VNS response, which might allow clinicians to personalize treatment decisions for DRE patients.